RIT with Y90-Ibritumomab Tiuxetan in Follicular Non-Hodgkin Lymphoma : Evaluation of Recent Outcomes in a Single Institution

Abstract EN

Background.

Based on historical data we reviewed our hospital clinical database to analyse our updated information and therapy outcomes of follicular non-Hodgkin lymphoma (F-NHL) patients treated with 90Y-Ibritumomab tiuxetan.

Patients and Methods.

Between 2005 and 2011, 56 F-NHL patients were included in a clinical protocol conducted by a multidisciplinary team and treated in the same centre.

All patients received 0.3 or 0.4 mCi/kg IV (88%) of 90Y-IT; response evaluation was performed 12 weeks after.

Results.

M/F 44.6%/55.4%, mean age 61.45 years (30–85); ECOG 0-1 96.9%.

According to FLIPI score, distribution were good: 58.5%, intermediate: 29.2%, and poor: 12.3%.

Previous therapies: >2: 40% (26).

ORR was 94.6% (53/56).

CR: 85.7%; CR according to previous disease: relapsed disease: 90% (27/30), refractory disease: 42.85% (3/7), consolidation with CR: 92.85% (13/14), and consolidation with PR: 100% (5/5).

Global PR and NR were 8.9% (5) and 5.3% (3), respectively.

Mean OS 63.86 months with a mean follow-up time of 57 months (2–73).

Mean TTP: 52.65 months (95% CI: 43.83–61.48).

Median OS and TTP were not achieved.

No hospital submissions or deaths were registered.

Conclusions.

This study confirms the safety and high efficacy of 90Y-IT in F-NHL patients, RIT in early stage of disease could improve outcomes.